B07 | LONG-TERM CLINICAL OUTCOMES WITH TISAGENLECLEUCEL IN HIGH-RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: 4-YEAR FOLLOW-UP FROM THE PHASE 2 ELARA STUDY

Background: Treatment approach for relapsed/refractory follicular lymphoma (r/r FL) depends on previous treatments and patients’ characteristics. Tisagenlecleucel is a Chimeric Antigen Receptor T-cell therapy (CAR-T) approved for adults with r/r FL after at least two prior lines of systemic therapy...

Descrizione completa

Dettagli Bibliografici

Autori principali:	P.L. Zinzani, C. Thieblemont, M. Dreyling, M.J. Dickinson, J. Martínez-Lopez, A. Kolstad, J. Butler, M. Ghosh, L.L. Popplewell, J.C. Chavez, E. Bachy, K. Kato, H. Harigae, M.J. Kersten, C. Andreadis, P.A. Riedell, P.J. Ho, J.A. Pérez-Simón, A. Chen, L. Nastoupil, B. Von Tresckow, A.J.M. Ferreri, T. Teshima, P.E.M. Patten, J.P. Mcguirk, F. Offner, A. Viardot, R. Malladi, A. Zia, R. Awasthi, D. Germano, R.J. Ramos, P. Hsu, S.J. Schuster, N.H. Fowler
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Ferrata Storti Foundation 2025-09-01
Serie:	Haematologica
Accesso online:	https://haematologica.org/article/view/12859
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!